Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Phase II study of cisplatin and 5‐fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185)
Authors
Omer Kucuk
Kishan J. Pandya
Roland T. Skeel
Howard Hochster
Martin D. Abeloff
Publication date
01-09-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006229701954

Other articles of this Issue 2/1999

Breast Cancer Research and Treatment 2/1999 Go to the issue

OriginalPaper

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

OriginalPaper

Glycogen‐rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments

OriginalPaper

17β‐hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue

OriginalPaper

5‐HT3 antiemetic therapy for patients with breast cancer

OriginalPaper

Staging efficacy of breast cancer with sentinel lymphadenectomy

OriginalPaper

Color Doppler ultrasound in benign and malignant breast tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits